NMOSD candidate therapy BAT4406F depletes B-cells, eases disability
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
Geoff’s Translation GIST Health Rising recently covered two big complex studies – one from the Lipkin group and the DecodeME genetic studies – and now here’s the BioMapAI study “AI-driven multi-omics modeling of myalgic encephalomyelitis/chronic fatigue syndrome” which uses a very different approach. The authors are very high on this […] The post Gut Reactions: BioMapAI Points to Multiple Dysregulated Systems in ME/CFS appeared first on Health Rising.| Health Rising
Immune B-cells that contain the receptor protein CD226 may play a role in the development and clinical manifestations of primary Sjögren’s disease, making CD226 a possible target for future treatments, a study reports. Data indicated that people with Sjögren’s had proportionally more CD226-positive B-cells in their bloodstream than their healthy counterparts. The prevalence of these […] The post B-cells containing CD226 may be Sjögren’s biomarker, therapy target appeared first on S...| Sjogren's Disease News – The Web's Daily Resource for Sjogren's Disease News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
